Exact Mass: 650.3508246

Exact Mass Matches: 650.3508246

Found 46 metabolites which its exact mass value is equals to given mass value 650.3508246, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

PA(8:0/6 keto-PGF1alpha)

[(2R)-2-({7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]cyclopentyl]-6-oxoheptanoyl}oxy)-3-(octanoyloxy)propoxy]phosphonic acid

C31H55O12P (650.343096)


PA(8:0/6 keto-PGF1alpha) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/6 keto-PGF1alpha), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of 6-Keto-prostaglandin F1alpha at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(6 keto-PGF1alpha/8:0)

[(2R)-3-({7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]cyclopentyl]-6-oxoheptanoyl}oxy)-2-(octanoyloxy)propoxy]phosphonic acid

C31H55O12P (650.343096)


PA(6 keto-PGF1alpha/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(6 keto-PGF1alpha/8:0), in particular, consists of one chain of one 6-Keto-prostaglandin F1alpha at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(8:0/TXB2)

[(2R)-2-{[(5Z)-7-[(2R,3S,4S)-4,6-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]oxan-3-yl]hept-5-enoyl]oxy}-3-(octanoyloxy)propoxy]phosphonic acid

C31H55O12P (650.343096)


PA(8:0/TXB2) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/TXB2), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of Thromboxane B2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(TXB2/8:0)

[(2R)-3-{[(5Z)-7-[(2R,3S,4S)-4,6-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]oxan-3-yl]hept-5-enoyl]oxy}-2-(octanoyloxy)propoxy]phosphonic acid

C31H55O12P (650.343096)


PA(TXB2/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(TXB2/8:0), in particular, consists of one chain of one Thromboxane B2 at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

Myrtucommulone D

Myrtucommulone D

C38H50O9 (650.345465)


   
   
   

Myrtucommulone C

Myrtucommulone C

C38H50O9 (650.345465)


   

3-acetyl-3-dodecanoyl-4-(3-methylbutanoyl)sucrose

3-acetyl-3-dodecanoyl-4-(3-methylbutanoyl)sucrose

C31H54O14 (650.3513384)


   

OHOHA-PG

1-(9Z-octadecenoyl)-2-(4-hydroxy-7-oxo-5E-heptenoyl)-sn-glycero-3-phospho-(1-sn-glycerol)

C31H55O12P (650.343096)


   

1-[4-(2-AZEPAN-1-YL-ETHOXY)-BENZYL]-5-BENZYLOXY-2-(4-BENZYLOXY-PHENYL)-3-METHYL-1H-INDOLE

1-[4-(2-AZEPAN-1-YL-ETHOXY)-BENZYL]-5-BENZYLOXY-2-(4-BENZYLOXY-PHENYL)-3-METHYL-1H-INDOLE

C44H46N2O3 (650.3508246)


   

3-Acetyl-3-lauryl-4-(isovaleryl)sucrose

3-Acetyl-3-lauryl-4-(isovaleryl)sucrose

C31H54O14 (650.3513384)


   

Sucrose 2-acetyl-3-lauroyl-3-isovalerate

Sucrose 2-acetyl-3-lauroyl-3-isovalerate

C31H54O14 (650.3513384)


   

Sucrose 2-isovaleroyl-3-isodecanoyl-4-isobutanoate

Sucrose 2-isovaleroyl-3-isodecanoyl-4-isobutanoate

C31H54O14 (650.3513384)


   

PA(8:0/6 keto-PGF1alpha)

PA(8:0/6 keto-PGF1alpha)

C31H55O12P (650.343096)


   

PA(6 keto-PGF1alpha/8:0)

PA(6 keto-PGF1alpha/8:0)

C31H55O12P (650.343096)


   
   
   

[2-hydroxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropyl] (10Z,13Z,16Z)-docosa-10,13,16-trienoate

[2-hydroxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropyl] (10Z,13Z,16Z)-docosa-10,13,16-trienoate

C31H55O12P (650.343096)


   
   
   
   
   
   
   
   
   
   
   
   
   

PI P-18:1/4:1 or PI O-18:2/4:1

PI P-18:1/4:1 or PI O-18:2/4:1

C31H55O12P (650.343096)


   
   

PI P-22:2 or PI O-22:3

PI P-22:2 or PI O-22:3

C31H55O12P (650.343096)


   
   
   

n-[1-({[(8e,10e,16z)-3,15,22,24-tetrahydroxy-5-methoxy-14,16-dimethyl-2-azabicyclo[18.3.1]tetracosa-1(24),2,6,8,10,16,20,22-octaen-13-yl]oxy}carbonyl)cyclopropyl]cyclohexanecarboximidic acid

n-[1-({[(8e,10e,16z)-3,15,22,24-tetrahydroxy-5-methoxy-14,16-dimethyl-2-azabicyclo[18.3.1]tetracosa-1(24),2,6,8,10,16,20,22-octaen-13-yl]oxy}carbonyl)cyclopropyl]cyclohexanecarboximidic acid

C37H50N2O8 (650.356698)


   

(2r,3ar,6r,7ar)-1-[(2r)-2-{[(2r)-2-(acetyloxy)-1-hydroxy-3-(4-hydroxyphenyl)propylidene]amino}-3-phenylpropanoyl]-n-(4-carbamimidamidobutyl)-6-hydroxy-octahydroindole-2-carboximidic acid

(2r,3ar,6r,7ar)-1-[(2r)-2-{[(2r)-2-(acetyloxy)-1-hydroxy-3-(4-hydroxyphenyl)propylidene]amino}-3-phenylpropanoyl]-n-(4-carbamimidamidobutyl)-6-hydroxy-octahydroindole-2-carboximidic acid

C34H46N6O7 (650.3427806)


   

4,8,8,12,21,25,25,29-octamethyl-13,30-dioxanonacyclo[17.15.1.1²,¹⁴.0³,¹².0⁴,⁹.0²⁰,²⁹.0²¹,²⁶.0³¹,³⁵.0¹⁸,³⁶]hexatriaconta-1,14,18(36),19(35),31-pentaene-16,17,33,34-tetrone

4,8,8,12,21,25,25,29-octamethyl-13,30-dioxanonacyclo[17.15.1.1²,¹⁴.0³,¹².0⁴,⁹.0²⁰,²⁹.0²¹,²⁶.0³¹,³⁵.0¹⁸,³⁶]hexatriaconta-1,14,18(36),19(35),31-pentaene-16,17,33,34-tetrone

C42H50O6 (650.3607199999999)


   

10a,13-dihydroxy-6,14-diisopropyl-2,2,4,4,8,8,10,10-octamethyl-12-(2-methylpropanoyl)-6a,14-dihydro-6h-5,11-dioxapentaphene-1,3,7,9-tetrone

10a,13-dihydroxy-6,14-diisopropyl-2,2,4,4,8,8,10,10-octamethyl-12-(2-methylpropanoyl)-6a,14-dihydro-6h-5,11-dioxapentaphene-1,3,7,9-tetrone

C38H50O9 (650.345465)


   

(6s,6as,10ar,14r)-10a,13-dihydroxy-6,14-diisopropyl-2,2,4,4,8,8,10,10-octamethyl-12-(2-methylpropanoyl)-6a,14-dihydro-6h-5,11-dioxapentaphene-1,3,7,9-tetrone

(6s,6as,10ar,14r)-10a,13-dihydroxy-6,14-diisopropyl-2,2,4,4,8,8,10,10-octamethyl-12-(2-methylpropanoyl)-6a,14-dihydro-6h-5,11-dioxapentaphene-1,3,7,9-tetrone

C38H50O9 (650.345465)


   

(6s,6ar,10as,14r)-10a,13-dihydroxy-6,14-diisopropyl-2,2,4,4,8,8,10,10-octamethyl-12-(2-methylpropanoyl)-6a,14-dihydro-6h-5,11-dioxapentaphene-1,3,7,9-tetrone

(6s,6ar,10as,14r)-10a,13-dihydroxy-6,14-diisopropyl-2,2,4,4,8,8,10,10-octamethyl-12-(2-methylpropanoyl)-6a,14-dihydro-6h-5,11-dioxapentaphene-1,3,7,9-tetrone

C38H50O9 (650.345465)


   

6,8-dihydroxy-7-[1-(2-hydroxy-3,3,5,5-tetramethyl-4,6-dioxocyclohex-1-en-1-yl)-2-methylpropyl]-9-isopropyl-2,2,4,4-tetramethyl-5-(2-methylpropanoyl)-9h-xanthene-1,3-dione

6,8-dihydroxy-7-[1-(2-hydroxy-3,3,5,5-tetramethyl-4,6-dioxocyclohex-1-en-1-yl)-2-methylpropyl]-9-isopropyl-2,2,4,4-tetramethyl-5-(2-methylpropanoyl)-9h-xanthene-1,3-dione

C38H50O9 (650.345465)


   

(2r,3r,4s,5r,6r)-5-hydroxy-2-{[(2s,3s,4r,5r)-4-hydroxy-2,5-bis(hydroxymethyl)-3-{[(2s)-2-methylbutanoyl]oxy}oxolan-2-yl]oxy}-6-(hydroxymethyl)-4-[(2-methylpropanoyl)oxy]oxan-3-yl decanoate

(2r,3r,4s,5r,6r)-5-hydroxy-2-{[(2s,3s,4r,5r)-4-hydroxy-2,5-bis(hydroxymethyl)-3-{[(2s)-2-methylbutanoyl]oxy}oxolan-2-yl]oxy}-6-(hydroxymethyl)-4-[(2-methylpropanoyl)oxy]oxan-3-yl decanoate

C31H54O14 (650.3513384)


   

(9r)-6,8-dihydroxy-7-[(1s)-1-(2-hydroxy-3,3,5,5-tetramethyl-4,6-dioxocyclohex-1-en-1-yl)-2-methylpropyl]-9-isopropyl-2,2,4,4-tetramethyl-5-(2-methylpropanoyl)-9h-xanthene-1,3-dione

(9r)-6,8-dihydroxy-7-[(1s)-1-(2-hydroxy-3,3,5,5-tetramethyl-4,6-dioxocyclohex-1-en-1-yl)-2-methylpropyl]-9-isopropyl-2,2,4,4-tetramethyl-5-(2-methylpropanoyl)-9h-xanthene-1,3-dione

C38H50O9 (650.345465)


   

1-(2-{[2-(acetyloxy)-1-hydroxy-3-(4-hydroxyphenyl)propylidene]amino}-3-phenylpropanoyl)-n-(4-carbamimidamidobutyl)-6-hydroxy-octahydroindole-2-carboximidic acid

1-(2-{[2-(acetyloxy)-1-hydroxy-3-(4-hydroxyphenyl)propylidene]amino}-3-phenylpropanoyl)-n-(4-carbamimidamidobutyl)-6-hydroxy-octahydroindole-2-carboximidic acid

C34H46N6O7 (650.3427806)